Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: Mol Cancer Ther. 2012 Aug 15;11(11):2331–2341. doi: 10.1158/1535-7163.MCT-12-0164

Figure 4. In situ vaccination with SRA/CD204-silenced DCs enhances the antitumor efficacy of RT.

Figure 4

A. RM1 tumor-bearing mice (n=5) received RT alone, RT plus DC-scram or DC-SRA shRNA, or left untreated. Tumor growth (left) and survival of RM1 tumor-bearing mice (right) were monitored. ** p<0.01, RT+DC-SRA shRNA vs RT+DC-scram. B. Enhanced suppression of TRAMP-C2 prostate tumor by SRA/CD204-targeted combinatorial therapy. * p < 0.01. C–D. Treatment of local prostate tumors with RT plus DC-SRA shRNA reduces distant metastases. Mice (n=5) were simultaneously established with s.c. ‘primary’ RM1 tumors in the flank and lung metastases through i.v. injection of RM1-luciferase cells. Tumors in the flank were subjected to treatment only. The metastases in the lungs were assessed using bioluminescence imaging (C). Lung tissues were collected from RM1-tumor (left) or TRAMP-C2 tumor (right)-bearing mice following treatment of s.c. tumors, and metastatic tumor nodules in the lungs were counted (D). * p < 0.05, ** p < 0.01. Data are representative of two experiments with similar results.